INTELLIGENTZIA
CAPITAL MANAGEMENT

CONFIDENTIAL & PRELIMINARY | APRIL 2026

Project Jacaranda

Investment Teaser

US FDA, TGA and EU GMP approved specialty pharmaceutical company seeking US $14 million to expand sterile manufacturing capabilities.

Expansion supports new cleanrooms, a sterile line, high-potency infrastructure and QC laboratory modernization. Commercial model spans in-house products, contract manufacturing and institutional / tender supply, with projected 2031 revenue of $40 million.

INDUSTRY	HEADQUARTERS	CAPITAL SOUGHT	2031E REVENUE
Specialty Pharma / CDMO	Location available upon NDA	US$ 14.0M	US $40M

Overview & Investment Highlights

Project Jacaranda | Confidential Teaser

INTELLIGENTZIA
CAPITAL MANAGEMENT

COMPANY OVERVIEW

- Specialized pharmaceutical company with advanced manufacturing and packing capabilities plus a robust in-house development portfolio.
- Approved by US FDA, TGA and EU GMP, with repeat success across major international inspections.
- Commercial model spans in-house products, contract manufacturing and institutional / tender supply.

TRANSACTION OVERVIEW

- Seeking US $14 million strategic partnership to expand into higher-margin sterile manufacturing capabilities.
- Proceeds to fund WH2 cleanrooms, a new sterile line, high-potency infrastructure and QC lab modernization.
- Expansion adds sterile injectables plus oral solid / liquid lines to support future scale-up.

INVESTMENT HIGHLIGHTS

01 Globally compliant platform

US FDA, TGA and EU GMP approvals underpin quality credibility and partner confidence.

02 Attractive niche exposure

Focus on specialty, rare-disease and differentiated formulations with identified unmet needs.

03 Visible expansion levers

Sterile buildout supports in-house pipeline, CMO demand creates upside through global supplies.

04 Experienced leadership

Management averages 20+ years across operations, quality, regulatory and business strategy.

SELECTED FINANCIAL SNAPSHOT

Metric	FY2025E	FY2028E	FY2031E
Revenue (US$M)	4.7	17	40
EBITDA (US$M)	(3.2)	3.6	21
EBITDA Margin	(69.2%)	20.8%	53.2%
Capital Sought (US$M)	14.0	-	-

Business Model & Commercial Positioning

Project Jacaranda | Confidential Teaser

INTELLIGENTZIA
CAPITAL MANAGEMENT

PRODUCT / SERVICE OVERVIEW

- Specialized pharmaceutical manufacturing platform with commercial production and packing capabilities.
- Expansion targets sterile injectables alongside oral solid / liquid dosage forms.
- Built to support high-value, specialty and rare-disease products under global regulatory standards.

BUSINESS MODEL

- B2C manufacturing of own in-house developed products.
- B2B contract manufacturing for external partners.
- Institutional and tender supply adds diversified channels.

END MARKETS & FOOTPRINT

- Addresses domestic and international unmet needs in niche and specialty pharma.
- Australia-based facility with export ambitions supported by Austrade relationships.
- New capacity broadens relevance across multiple dosage forms and partner mandates.

KEY DIFFERENTIATORS

01 Mission-critical quality platform

Major approvals and repeat inspection success support regulated market participation.

02 Diversified commercial model

Own products, CMO work and institutional supply provide multiple routes to scale.

03 Scalable operating footprint

Existing manufacturing base plus available space support efficient expansion.

04 Multiple value-creation levers

Sterile buildout, pipeline commercialization and new partner fill-up create upside.

Expansion Strategy & Capital Deployment

Project Jacaranda | Confidential Teaser

INTELLIGENTZIA
CAPITAL MANAGEMENT

USE OF PROCEEDS

- Expansion into higher-margin manufacturing capabilities for specialty and value-added products.
- Construction of new cleanrooms in WH2 to support sterile and controlled environments.
- Capital expenditure for a new sterile manufacturing line and infrastructure for high-potency handling.
- Upgrade and modernization of the in-house Quality Control laboratory to enhance analytical capacity and compliance.

US $14.0M strategic partnership

New dosage form lines:
Sterile Injectables & Oral Solid / Liquids

GROWTH LEVERS & FORECAST

Sterile line buildout	Niche product focus	Multi-format platform	CMO demand capture
Controlled sterile capacity	Rare disease & differentiated forms	Vials, PFS and cartridges	Existing + new partner interest

Management forecast shows revenue increasing to US$40M and EBITDA reaching US$21M by 2031, with positive EBITDA by 2028E.



Regulatory Footprint & Operating Excellence

Project Jacaranda | Confidential Teaser

INTELLIGENTZIA
CAPITAL MANAGEMENT

REGULATORY CREDENTIALS

- US FDA, TGA and EU GMP approved specialized pharmaceutical company.
- Flyer cites a successful US FDA audit (Oct 2025) and EAEU audit (Mar 2025).
- Proven track record of passing TGA, EU-GMP and ANVISA inspections multiple times.
- Global compliance supports both domestic and export-market credibility.

OPERATIONAL STRENGTHS

- Commercial manufacturing and packing capabilities are already in place.
- Significant additional space is available to support future scale-up.
- Planned cleanrooms, sterile line and high-potency infrastructure support-controlled production.
- QC lab upgrades expand analytical capacity and strengthen compliance readiness.

APPROVALS & VALIDATION

TEAM & GOVERNMENT SUPPORT Need discussion

- Leadership averages 20+ years across operations, quality, regulatory and strategy.
- Australian Exporter of the Year finalist in 2024 and 2025.
- Austrade relationships can support global commercial reach.